Published in Kidney Int on March 01, 2005
The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev (2007) 6.79
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov (2011) 3.26
Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol (2009) 2.12
T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol (2010) 1.84
Mechanisms of progression of chronic kidney disease. Pediatr Nephrol (2007) 1.52
Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol Dial Transplant (2009) 1.10
Genotype-phenotype analysis of angiotensinogen polymorphisms and essential hypertension: the importance of haplotypes. J Hypertens (2010) 0.97
Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol (2007) 0.95
A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol (2010) 0.95
Adverse host factors exacerbate occult HIV-associated nephropathy. Am J Pathol (2011) 0.94
Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease. Nat Clin Pract Nephrol (2008) 0.93
Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med (2010) 0.93
The top 10 things nephrologists wish every primary care physician knew. Mayo Clin Proc (2009) 0.90
Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids (2010) 0.90
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair (2011) 0.87
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag (2010) 0.87
Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system. Biomed Res Int (2015) 0.86
Inhibition of renin activity slows down the progression of HIV-associated nephropathy. Am J Physiol Renal Physiol (2012) 0.84
Angiotensin receptor blockade has protective effects on the poststenotic porcine kidney. Kidney Int (2013) 0.84
Randomized, double-blind, controlled study of losartan in children with proteinuria. Clin J Am Soc Nephrol (2010) 0.83
Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study. BMC Nephrol (2012) 0.82
AT1 receptor antagonism does not influence early radiation-induced changes in microglial activation or neurogenesis in the normal rat brain. Radiat Res (2011) 0.82
Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clin Exp Nephrol (2015) 0.82
Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db/db mice. Br J Pharmacol (2015) 0.80
Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease? Oxid Med Cell Longev (2015) 0.79
RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract (2013) 0.78
Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy. J Diabetes Investig (2012) 0.78
Genome-wide methylation profiling of ADPKD identified epigenetically regulated genes associated with renal cyst development. Hum Genet (2013) 0.78
Determination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell culture (SILAC). J Biol Chem (2013) 0.78
Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension. Pharmacol Res (2016) 0.77
Long-Term and Interactive Effects of Pay-For-Performance Interventions among Diabetic Nephropathy Patients at the Early Chronic Kidney Disease Stage. Medicine (Baltimore) (2016) 0.77
The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis. Clin Exp Nephrol (2014) 0.77
Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model. Clin Exp Nephrol (2008) 0.76
Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: new therapeutic world beyond blood pressure reduction. Kidney Int (2005) 0.76
Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease. Am J Physiol Renal Physiol (2013) 0.75
Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen. Biomed Res Int (2016) 0.75
Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome? Int J Nephrol (2012) 0.75
Combination renin-angiotensin system blockade in hypertension. Kidney Int (2005) 0.75
Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure. Indian J Pharmacol (2015) 0.75
Impaired endocytosis in proximal tubule from subchronic exposure to cadmium involves angiotensin II type 1 and cubilin receptors. BMC Nephrol (2013) 0.75
Renal interstitial fibrosis and Angiotensin inhibition. Electrolyte Blood Press (2006) 0.75
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med (2011) 11.11
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Nephron number in patients with primary hypertension. N Engl J Med (2003) 6.74
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol (2009) 4.31
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 3.48
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant (2010) 2.64
Essential hypertension. Lancet (2007) 2.63
Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol (2009) 2.13
Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol (2010) 2.13
Preparation of the dialysis patient for transplantation. Nephrol Dial Transplant (2002) 2.10
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 2.00
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol (2005) 1.96
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem (2010) 1.95
1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol (2003) 1.86
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
Nutritional status in dialysis patients: a European consensus. Nephrol Dial Transplant (2002) 1.81
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol (2005) 1.74
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J (2010) 1.72
Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant (2011) 1.71
Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol (2002) 1.70
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol (2002) 1.70
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int (2012) 1.65
Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation (2003) 1.63
A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int (2008) 1.61
Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant (2013) 1.55
Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J (2011) 1.55
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens (Greenwich) (2009) 1.54
Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta (2010) 1.46
High salt intake causes adverse fetal programming--vascular effects beyond blood pressure. Nephrol Dial Transplant (2012) 1.46
No aggravation of renal injury in apolipoprotein E knockout mice (ApoE(-/-)) after subtotal nephrectomy. Nephrol Dial Transplant (2004) 1.45
High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens (2004) 1.43
Salt-sensitive blood pressure--an intermediate phenotype predisposing to diabetic nephropathy? Nephrol Dial Transplant (2005) 1.40
The living kidney donor: giving life, avoiding harm. Nephrol Dial Transplant (2003) 1.40
Acute phase reaction to gadolinium-DTPA in dialysis patients. Nephrol Dial Transplant (2008) 1.39
Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol (2003) 1.39
The arteriovenous fistula. J Am Soc Nephrol (2003) 1.31
Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J (2010) 1.30
Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol (2013) 1.26
Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int (2008) 1.26
The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol (2003) 1.26
Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol (2008) 1.25
Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol (2006) 1.25
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens (2006) 1.25
Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease. Semin Dial (2008) 1.24
Vitamin D, cardiovascular disease and mortality. Clin Endocrinol (Oxf) (2011) 1.24
Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J (2010) 1.23
Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol (2006) 1.22
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol (2011) 1.19
Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem (2010) 1.19
Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res (2004) 1.18
Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int (2003) 1.17
Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res (2012) 1.14
The epidemiology of end-stage renal disease in Iran in an international perspective. Nephrol Dial Transplant (2002) 1.12
Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation (2009) 1.10
Why patients with progressing kidney disease are referred late to the nephrologist: on causes and proposals for improvement. Nephrol Dial Transplant (2005) 1.09
Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol (2004) 1.08
Do AV fistulas contribute to cardiac mortality in hemodialysis patients? Semin Dial (2002) 1.08
Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol (2005) 1.07
Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol (2008) 1.07
Malignancy after renal transplantation. Am J Kidney Dis (2002) 1.07
Both high and low maternal salt intake in pregnancy alter kidney development in the offspring. Am J Physiol Renal Physiol (2011) 1.06
Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int (2003) 1.06
Aldosterone and arterial hypertension. Nat Rev Endocrinol (2009) 1.06
Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant (2002) 1.05
Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism (2013) 1.04
Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant (2009) 1.04
Homoarginine, cardiovascular risk, and mortality. Circulation (2010) 1.04
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int (2010) 1.04
Retinoid receptor-specific agonists alleviate experimental glomerulonephritis. Am J Physiol Renal Physiol (2002) 1.04
The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant (2009) 1.04
Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis (2007) 1.02
Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab (2011) 1.01
Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol (2004) 1.01
Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 1.01
B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem (2007) 1.00
Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats. J Am Soc Nephrol (2004) 1.00
The renal risks of smoking: an update. Curr Opin Nephrol Hypertens (2002) 1.00
Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am J Kidney Dis (2010) 0.99
Alanine to serine polymorphism at position 986 of the calcium-sensing receptor associated with coronary heart disease, myocardial infarction, all-cause, and cardiovascular mortality. J Clin Endocrinol Metab (2007) 0.99
Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. Am J Physiol Renal Physiol (2008) 0.98
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension (2003) 0.98
High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathy. PLoS One (2011) 0.98
Albuminuria and vascular damage--the vicious twins. N Engl J Med (2003) 0.98
Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int (2009) 0.97
Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol (2003) 0.97
Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol (2004) 0.97
ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cells. Kidney Int (2002) 0.97
Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients. Eur J Heart Fail (2011) 0.96
Sympathetic overactivity--the Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial (2008) 0.96
Wasting and sudden cardiac death in hemodialysis patients: a post hoc analysis of 4D (Die Deutsche Diabetes Dialyse Studie). Am J Kidney Dis (2011) 0.96
Alcohol and kidney damage: a Janus-faced relationship. Kidney Int (2012) 0.95
Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest (2003) 0.95
Late referral--a major cause of poor outcome in the very elderly dialysis patient. Nephrol Dial Transplant (2006) 0.95
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Kidney Int (2009) 0.94
Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol (2003) 0.91
Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant (2008) 0.91